🚀 VC round data is live in beta, check it out!
Revenio Group Valuation Multiples
Discover revenue and EBITDA valuation multiples for Revenio Group and similar public comparables like NeuroPace, Orthofix Medical, Sofwave Medical, MiMedx Group and more.
Revenio Group Overview
About Revenio Group
Revenio Group Oyj is a Finnish health technology company. It develops and commercializes effective and easy-to-use health tech-related screening devices for detecting diseases of significance to public health. Its ophthalmic diagnostic solutions includes intraocular pressure (IOP) measurement devices (tonometers), and perimeter and fundus imaging devices under the iCare brand. Its eye care software platform Oculo offers clinical communication, telehealth, remote patient monitoring, and data analytics capabilities. The company's geographical segments include Finland, USA, and Others.
Founded
2001
HQ
Employees
241
Website
Financials (LTM)
EV
$514M
Revenio Group Financials
Revenio Group reported last 12-month revenue of $133M and EBITDA of $37M.
In the same LTM period, Revenio Group generated $75M in gross profit, $37M in EBITDA, and $22M in net income.
Revenue (LTM)
Revenio Group P&L
In the most recent fiscal year, Revenio Group reported revenue of $130M and EBITDA of $36M.
Revenio Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $133M | XXX | $130M | XXX | XXX | XXX |
| Gross Profit | $75M | XXX | $92M | XXX | XXX | XXX |
| Gross Margin | 56% | XXX | 70% | XXX | XXX | XXX |
| EBITDA | $37M | XXX | $36M | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 28% | XXX | XXX | XXX |
| EBIT Margin | 24% | XXX | 24% | XXX | XXX | XXX |
| Net Profit | $22M | XXX | $21M | XXX | XXX | XXX |
| Net Margin | 17% | XXX | 16% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Revenio Group Stock Performance
Revenio Group has current market cap of $532M, and enterprise value of $514M.
Market Cap Evolution
Revenio Group's stock price is $19.98.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $514M | $532M | 0.0% | XXX | XXX | XXX | $0.78 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialRevenio Group Valuation Multiples
Revenio Group trades at 3.9x EV/Revenue multiple, and 13.9x EV/EBITDA.
EV / Revenue (LTM)
Revenio Group Financial Valuation Multiples
As of April 20, 2026, Revenio Group has market cap of $532M and EV of $514M.
Equity research analysts estimate Revenio Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Revenio Group has a P/E ratio of 23.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $532M | XXX | $532M | XXX | XXX | XXX |
| EV (current) | $514M | XXX | $514M | XXX | XXX | XXX |
| EV/Revenue | 3.9x | XXX | 3.9x | XXX | XXX | XXX |
| EV/EBITDA | 13.9x | XXX | 14.3x | XXX | XXX | XXX |
| EV/EBIT | 16.1x | XXX | 16.7x | XXX | XXX | XXX |
| EV/Gross Profit | 6.8x | XXX | 5.6x | XXX | XXX | XXX |
| P/E | 23.9x | XXX | 25.6x | XXX | XXX | XXX |
| EV/FCF | 19.3x | XXX | 16.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Revenio Group Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Revenio Group Margins & Growth Rates
Revenio Group's revenue in the last 12 month grew by 9%.
Revenio Group's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.3M for the same period.
Revenio Group's rule of 40 is 37% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Revenio Group's rule of X is 51% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Revenio Group Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 28% | XXX | XXX | XXX |
| EBITDA Growth | 13% | XXX | 11% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 37% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 51% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 0% | XXX | 8% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1% | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 47% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Revenio Group Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Revenio Group | XXX | XXX | XXX | XXX | XXX | XXX |
| NeuroPace | XXX | XXX | XXX | XXX | XXX | XXX |
| Orthofix Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Sofwave Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| MiMedx Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Polynovo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Revenio Group M&A Activity
Revenio Group acquired XXX companies to date.
Last acquisition by Revenio Group was on XXXXXXXX, XXXXX. Revenio Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Revenio Group
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialRevenio Group Investment Activity
Revenio Group invested in XXX companies to date.
Revenio Group made its latest investment on XXXXXXXX, XXXXX. Revenio Group invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Revenio Group
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Revenio Group
| When was Revenio Group founded? | Revenio Group was founded in 2001. |
| Where is Revenio Group headquartered? | Revenio Group is headquartered in Finland. |
| How many employees does Revenio Group have? | As of today, Revenio Group has over 241 employees. |
| Who is the CEO of Revenio Group? | Revenio Group's CEO is Jouni Toijala. |
| Is Revenio Group publicly listed? | Yes, Revenio Group is a public company listed on Nasdaq Helsinki. |
| What is the stock symbol of Revenio Group? | Revenio Group trades under REG1V ticker. |
| When did Revenio Group go public? | Revenio Group went public in 2001. |
| Who are competitors of Revenio Group? | Revenio Group main competitors are NeuroPace, Orthofix Medical, Sofwave Medical, MiMedx Group. |
| What is the current market cap of Revenio Group? | Revenio Group's current market cap is $532M. |
| What is the current revenue of Revenio Group? | Revenio Group's last 12 months revenue is $133M. |
| What is the current revenue growth of Revenio Group? | Revenio Group revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Revenio Group? | Current revenue multiple of Revenio Group is 3.9x. |
| Is Revenio Group profitable? | Yes, Revenio Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Revenio Group? | Revenio Group's last 12 months EBITDA is $37M. |
| What is Revenio Group's EBITDA margin? | Revenio Group's last 12 months EBITDA margin is 28%. |
| What is the current EV/EBITDA multiple of Revenio Group? | Current EBITDA multiple of Revenio Group is 13.9x. |
| What is the current FCF of Revenio Group? | Revenio Group's last 12 months FCF is $27M. |
| What is Revenio Group's FCF margin? | Revenio Group's last 12 months FCF margin is 20%. |
| What is the current EV/FCF multiple of Revenio Group? | Current FCF multiple of Revenio Group is 19.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.